Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Januvia (sitagliptin by Quarter
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide reported growth YoY (%) (%)
Merck Januvia (sitagliptin: -31.0% in Q2 2026, down 23.0 pts from a year earlier.
Latest, Q2 2026
-31.0%
Period ended Jun 30, 2026
Change on a year earlier
-23.0 pts
-8.0% in Q2 2025
History
33 quarters
Since Q4 2017
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
“|| Januvia | 258 | 372 | -31 | 149 | 216 | -31 | 109 | 155 | -30”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Januvia (sitagliptin (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-januvia-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.